Tweet
In a recent study presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, researchers have identified distinct proteogenomic signatures in prostate cancer that vary according to patient ancestry—findings that could have implications for predicting disease progression and tailoring treatment. Conducted by a team led by Shyh-Han Tan, from the Uniformed Services University of the Health Sciences (USUHS), the study spans the field of proteogenomics, which integrates proteomic and genomic analyses to offer a more nuanced understanding of cancer biology.
Tan, explaining the premise of proteogenomics, compares DNA to an instruction manual for protein synthesis, where errors in the DNA sequence can result in defective proteins. "But errors in the instructions, or DNA mutations, can lead to the generation of faulty proteins," Tan notes, highlighting the dual focus on DNA and proteins as crucial for pinpointing where these errors occur. This approach, according to Tan, enables a more precise grasp of prostate cancer mechanisms, potentially leading to more targeted treatments.
The researchers utilized early-stage prostate cancer tissue samples from 57 patients of African ancestry and 55 of European ancestry, all sourced from the Center for Prostate Disease Research (CPDR). This unique dataset allowed the team to sidestep socioeconomic variables, focusing purely on molecular differences. Cara Schafer, the study's lead author, underscores the value of this approach in addressing health disparities, noting, "These proteogenomic comparisons can help us bridge the gap in our understanding of why prostate cancer remains more deadly in men of African ancestry."
Key findings from the study include varied protein expression linked to an increased risk of disease progression across ancestries. Notably, certain proteins in the oxidative phosphorylation pathway were more abundant in tumors from patients of African ancestry, suggesting potential therapeutic targets. Conversely, tumors from European ancestry patients showed elevated levels of proteins involved in cholesterol metabolism.
Moreover, the study unveiled distinct mutation signatures related to aging in European ancestry patients and DNA repair deficiencies in African ancestry patients, the latter possibly influencing responsiveness to specific therapies like PARP inhibitors. Gene alterations also varied between the groups, with certain chromosomal loci showing higher rates of deletion or amplification depending on ancestry.
Tan emphasizes the broader applicability of these findings, stating, "Differences in our genetic ancestry and the variations in gene mutation signatures can partly explain why some cancers are more aggressive than others and can reveal weaknesses in the cancer cells that can be used as a target for therapy." He also discussed the inclusive potential of proteogenomic studies in identifying actionable mutations across diverse patient groups.
In the future, the team plans to validate their findings against larger datasets and preclinical models to confirm the clinical relevance of specific gene alterations. While the study's sample size and the early-stage nature of the analyzed tumors present limitations, its insights into the proteogenomic background of prostate cancer offer promising avenues for more personalized and effective treatment strategies.
Tan, explaining the premise of proteogenomics, compares DNA to an instruction manual for protein synthesis, where errors in the DNA sequence can result in defective proteins. "But errors in the instructions, or DNA mutations, can lead to the generation of faulty proteins," Tan notes, highlighting the dual focus on DNA and proteins as crucial for pinpointing where these errors occur. This approach, according to Tan, enables a more precise grasp of prostate cancer mechanisms, potentially leading to more targeted treatments.
The researchers utilized early-stage prostate cancer tissue samples from 57 patients of African ancestry and 55 of European ancestry, all sourced from the Center for Prostate Disease Research (CPDR). This unique dataset allowed the team to sidestep socioeconomic variables, focusing purely on molecular differences. Cara Schafer, the study's lead author, underscores the value of this approach in addressing health disparities, noting, "These proteogenomic comparisons can help us bridge the gap in our understanding of why prostate cancer remains more deadly in men of African ancestry."
Key findings from the study include varied protein expression linked to an increased risk of disease progression across ancestries. Notably, certain proteins in the oxidative phosphorylation pathway were more abundant in tumors from patients of African ancestry, suggesting potential therapeutic targets. Conversely, tumors from European ancestry patients showed elevated levels of proteins involved in cholesterol metabolism.
Moreover, the study unveiled distinct mutation signatures related to aging in European ancestry patients and DNA repair deficiencies in African ancestry patients, the latter possibly influencing responsiveness to specific therapies like PARP inhibitors. Gene alterations also varied between the groups, with certain chromosomal loci showing higher rates of deletion or amplification depending on ancestry.
Tan emphasizes the broader applicability of these findings, stating, "Differences in our genetic ancestry and the variations in gene mutation signatures can partly explain why some cancers are more aggressive than others and can reveal weaknesses in the cancer cells that can be used as a target for therapy." He also discussed the inclusive potential of proteogenomic studies in identifying actionable mutations across diverse patient groups.
In the future, the team plans to validate their findings against larger datasets and preclinical models to confirm the clinical relevance of specific gene alterations. While the study's sample size and the early-stage nature of the analyzed tumors present limitations, its insights into the proteogenomic background of prostate cancer offer promising avenues for more personalized and effective treatment strategies.